Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy

Journal of Infectious Diseases

Volumn 187, Issue 1, 2003, Pages 144-148

  Tierney, Camlin ^a   Lathey, Janet L ^c   Christopherson, Cindy ^d   Bettendorf, Daniel M ^a   D'Aquila, Richard T ^b   Hammer, Scott M ^f   Katzenstein, David A ^e  

^a CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d ROCHE MOLECULAR SYSTEMS   (United States)

^e STANFORD UNIVERSITY   (United States)

^f Columbia Univ Coll of Phys/Surg ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; NUCLEOSIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CORRELATION ANALYSIS; DISEASE COURSE; DNA DETERMINATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL MODEL; SURVIVAL RATE; VIRUS CULTURE; VIRUS LOAD; VIRUS TITRATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DISEASE PROGRESSION; DNA, VIRAL; HIV-1; HUMANS; MULTIVARIATE ANALYSIS; PROGNOSIS; RNA, VIRAL; ZALCITABINE; ZIDOVUDINE;

EID: 0037217732     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/345870     Document Type: Article

References (15)

1. US Public Health Service (USPHS) and infectious Disease Society of America (IDSA). 1999 USPHS/ISDA guidelines for prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Recomm Rep 1999; 48(RR-10):1-59, 61-6.
2. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-70.
3. Phillips AN, Eron JJ, Bartlett JA, et al. HIV RNA levels and the development of clinical disease. North American lamivudine HIV working group. AIDS 1996; 10:859-65.
4. Christopherson C, Kidane Y, Conway B, et al. PCR-based assay to quantify human immunodeficiency virus type 1 in peripheral blood mononuclear cells. J Clin Microbiol 2000; 38:630-4
5. Mulder J, McKinney N, Christopherson C, et al. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: Application to acute retroviral infection. J Clin Microbiol 1994;32:292-300.
6. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996; 335:1081-90.
7. Katzenstein DA, Hammer SM, Hughes MD, et al. The relationship of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996; 335:1091-8.
8. 3 (ACTG 175). J Infect Dis 1998; 177:617-24.
9. Lathey JL, Tierney C, Chang SP, et al. Association of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy. J Infect Dis 2001; 184:1402-11.
10. + cells. J Acquir Immune Defic Syndr 1993; 6: 237-40
11. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512-517
12. Chun T, Fauci A. Latent reservoirs of HIV: Obstacles to the eradication of virus. Proc Natl Acad Sci USA 1999; 96:10958-61.
13. Sonza S, Mutimer HP, Oelrichs R, et al. Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy. AIDS 2001; 15:17-22.
14. Ramratman B, Mittler JE, Zhang L, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual replication during prolonged anti-retroviral therapy. Nat Med 2000; 6:82-5.
15. Holodniy MD, Kim S, Katzenstein DA, Konrad M, Groves E, Merigan TC. Inhibition of human immunodeficiency virus gene amplification by heparin. J Clin Microbiol 1991; 29:676-9.